Literature DB >> 30850249

Colonization by fecal extended-spectrum β-lactamase-producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery.

María Fernanda Golzarri1, Jesús Silva-Sánchez2, Patricia Cornejo-Juárez1, Humberto Barrios-Camacho2, Luis David Chora-Hernández1, Consuelo Velázquez-Acosta3, Diana Vilar-Compte4.   

Abstract

BACKGROUND: Cancer patients are at increased risk of infection. Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) may increase this risk. There are few studies on the prevalence of ESBL-PE colonization and surgical site infections (SSIs).
METHODS: This prospective cohort study included patients with gastrointestinal and gynecological malignancies who were admitted to the hospital for elective surgery. Rectal swab cultures were obtained on the day of admission and during the postoperative period every 5 days. Prevalence of ESBL-PE fecal colonization and risk factors for the development of SSI were assessed.
RESULTS: We included 171 patients, 30 (17.5%) of whom were colonized with ESBL-PE at admission. This proportion increased to 21% (37 of 171) of the samples during the hospital stay. Incidence of SSI was 14.6% (n = 25). Ten of 37 (27%) patients colonized by ESBL-PE developed SSI versus 15 of 134 (11%) of the non-ESBL-PE (relative risk [RR], 2.163; 95% confidence interval [CI], 1.201-3.897; P = .016). Five patients developed a bloodstream infection, and 4 patients were colonized with ESBL-PE (RR = 4.02; 95% CI, 1.2-3.89; P = .008).
CONCLUSIONS: The rate of ESBL-PE fecal colonization in surgical patients was 17.5%. Colonization of ESBL-PE duplicated the risk of SSI by the same strain and, by a factor of 4, the risk of bloodstream infections.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Abdominal neoplasms; Antibiotic prophylaxis; Cancer; Cross infection; Multidrug resistance

Mesh:

Year:  2019        PMID: 30850249     DOI: 10.1016/j.ajic.2019.01.020

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  6 in total

Review 1.  Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units.

Authors:  Dirk Vogelaers; Stijn Blot; Andries Van den Berge; Philippe Montravers
Journal:  Drugs       Date:  2021-05-26       Impact factor: 9.546

2.  Do Probiotics During In-Hospital Antibiotic Treatment Prevent Colonization of Gut Microbiota With Multi-Drug-Resistant Bacteria? A Randomized Placebo-Controlled Trial Comparing Saccharomyces to a Mixture of Lactobacillus, Bifidobacterium, and Saccharomyces.

Authors:  Grégoire Wieërs; Valérie Verbelen; Mieke Van Den Driessche; Ekaterina Melnik; Greet Vanheule; Jean-Christophe Marot; Patrice D Cani
Journal:  Front Public Health       Date:  2021-03-08

3.  A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection.

Authors:  Hui Liu; Suishan Qiu; Minghao Chen; Jun Lyu; Guangchao Yu; Lianfang Xue
Journal:  BMC Infect Dis       Date:  2022-01-13       Impact factor: 3.090

4.  Surgical site infections caused by multi-drug resistant organisms: a case-control study in general surgery.

Authors:  Diego Foschi; Al'ona Yakushkina; Francesco Cammarata; Giulia Lamperti; Francesco Colombo; Sara Rimoldi; Spinello Antinori; Gianluca M Sampietro
Journal:  Updates Surg       Date:  2022-03-19

5.  A novel prognostic model for malignant patients with Gram-negative bacteremia based on real-world research.

Authors:  Sujiao Ni; Pingyao Xu; Kaijiong Zhang; Haiming Zou; Huaichao Luo; Chang Liu; Yuping Li; Yan Li; Dongsheng Wang; Renfei Zhang; Ruiling Zu
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

6.  Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections.

Authors:  Alvaro J Martínez-Valencia; Brian J Gómez Martínez; Anita M Montañez Ayala; Katherin García; Ricardo Sánchez Pedraza; Leydy P Jiménez Cetina; Julio C Gómez Rincón; Sonia I Cuervo Maldonado
Journal:  BMC Infect Dis       Date:  2020-07-31       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.